- €833.14m
- €507.44m
- €314.33m
Brief: Philogen Resubmits To EMA Marketing Authorization Application For Nidlegy
Brief: Sun Pharma Says Partner Philogen's Phase II Flash Study In Soft Tissue Sarcoma Did Not Meet Primary Endpoint
Brief: Philogen Reports FY EBITDA Of EUR 261.6 Million
Brief: Philogen H1 Net Loss EUR 14,894
Brief: Philogen Withdraws Its EMA Marketing Authorization Application For Nidlegy
Brief: Philochem Announces Licensing Of Oncoacp3, To Rayzebio, A Bristol-Myers Squibb Company, For A Potential Value Of Up To $1.35Bn Plus Royalties
Brief: Philogen FY Total Revenue EUR 77.7 Mln
Brief: Philogen Starts Buyback For Up To EUR 5 Mln
Brief: Philogen Says Entered Into Global Licensing Agreement For Commercializing Fibromun
Brief: Philogen H1 Net Loss At EUR 15.5 Mln
Brief: Philogen FY Net Loss Widens To EUR 6.2 Mln
Brief: Philogen Net Financial Position At Sept-End Positive For EUR 68.6 Mln
Brief: Philogen H1 Net Profit Up To EUR 7.7 Mln
Brief: Philogen Net Financial Position At End-March EUR 66.7 Mln
Brief: Philogen FY Net Loss Shrinks To EUR 5.4 Mln
'It's money time' - Stifel resumes Philogen with 'buy'
Brief: Philogen H1 Net Result Turns To Profit Of EUR 2.0 Mln
Brief: Philogen Announces Enrolment Of 214 Patients In The Nidlegy™ Phase III European Clinical Trial For The Treatment Of Locally Advanced Melanoma
Brief: Philogen SpA Q1 Net Financial Position At EUR 76,352